If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.30    0.00 (0.00%)
Bid:
1.25
Ask:
1.35
Spread: 0.10 (8.00%)
Market Cap: £20.87m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Distribution agreement

9 Mar 2021 07:00

RNS Number : 5536R
Genedrive PLC
09 March 2021
 

 

 

genedrive plc

("genedrive" or the "Company")

 

Genedrive enters distribution agreement with Mountain Horse Solutions

Distribution of genedrive's Military Assays and Instrument in the United States

 

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that it has entered into an agreement for the distribution of the Company's military pathogen detection assays in the United States with Mountain Horse Solutions ("Mountain Horse"), a military contracting specialist to U.S. Federal, State, and Local Government customers.

 

genedrive has a unique product with regard to military CBRNE1 requirements. The Genedrive® BioPlex range of products was developed to the U.S. Department of Defense's (U.S. DoD) product specification with the help of U.S. DoD funding. Designed for field portability and rapid determination of biothreats from pathogens, the Genedrive BioPlex system was developed over a period of five years and has been approved to deployment stage.

 

Contracting with the U.S. Government can be challenging and time consuming. The Company believes that establishing new, local representation in the United States with identified contacts in this highly specialised field will help drive broader product uptake. Organisations like Mountain Horse are already contracted with the U.S. Government, which includes existing framework purchasing agreements, providing an opportunity for more rapid order placement and replenishment of products without the need for new contracts to be negotiated.

 

Bill Allen, President of Mountain Horse Solutions, said: "We are delighted to be working with genedrive with these exciting pathogen detection products. The addition of genedrive's assays to our portfolio of CBRNE mission critical products provides a unique offering of combat-ready sampling and detection devices."

 

David Budd, CEO of genedrive plc, said: "The agreement allows the supply of our BioPlex pathogen detection assays through Mountain Horse, a military contracting specialist who has a number of existing framework contracts with target clients such as the U.S. DoD. We believe that they have both the industry sector knowledge and existing commercial arrangements to increase the exposure of our products and gain new customer opportunities within the various branches and departments of the DoD and U.S. Government."

 

1. Chemical Biological Radiological, Nuclear and Explosive

 

For further details please contact:

 

genedrive plc

+44 (0)161 989 0245

David Budd: CEO / Matthew Fowler: CFO

 

 

 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel / Oliver Jackson

 

 

 

finnCap (Joint Broker)

+44 (0)20 7220 0500

Geoff Nash / Kate Bannatyne / Alice Lane

 

 

 

Walbrook PR Ltd (Media & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive® Point of Care version of the assay, both based on Genedrive® chemistry.

 

About Mountain Horse Solutions 

Mountain Horse Solutions supplies rapid response customized equipment, systems, and training for infectious disease, security, technology, chemical, biological, radiological, nuclear, and explosive (CBRNE) hazards. We specially design innovative solutions, to meet the individual unique threats, needs, and requirements of the military, and first responders. Our team of professionals from around the globe has extensive experience with commercial, DOD, and U.S. Federal Government customers. Mountain Horse Solutions serves organizations, agencies, and contractors worldwide. To find out more visit: www.mtnhorse.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRBIGDXBXGDGBI
Date   Source Headline
4th Aug 20207:00 amRNSCollaboration to automate COVID-19 PCR testing
23rd Jul 202011:06 amRNSSecond Price Monitoring Extn
23rd Jul 202011:00 amRNSPrice Monitoring Extension
22nd Jul 20203:13 pmRNSHolding(s) in Company
21st Jul 202011:05 amRNSSecond Price Monitoring Extn
21st Jul 202011:00 amRNSPrice Monitoring Extension
16th Jul 20204:29 pmRNSHolding(s) in Company
13th Jul 20209:00 amRNSPrice Monitoring Extension
10th Jul 20202:05 pmRNSSecond Price Monitoring Extn
10th Jul 20202:00 pmRNSPrice Monitoring Extension
10th Jul 20207:01 amRNSNew Genedrive® 96 Exporter software
10th Jul 20207:00 amRNSTrading update
1st Jul 20207:00 amRNSTotal Voting Rights
26th Jun 20203:24 pmRNSHolding(s) in Company
25th Jun 20203:39 pmRNSHolding(s) in Company
22nd Jun 20203:06 pmRNSHolding(s) in Company
22nd Jun 202011:08 amRNSHolding(s) in Company
18th Jun 202011:06 amRNSSecond Price Monitoring Extn
18th Jun 202011:00 amRNSPrice Monitoring Extension
17th Jun 20204:41 pmRNSSecond Price Monitoring Extn
17th Jun 20204:35 pmRNSPrice Monitoring Extension
17th Jun 20202:05 pmRNSSecond Price Monitoring Extn
17th Jun 20202:00 pmRNSPrice Monitoring Extension
16th Jun 202011:37 amRNSConversion of Convertible Bond
15th Jun 20204:40 pmRNSSecond Price Monitoring Extn
15th Jun 20204:36 pmRNSPrice Monitoring Extension
10th Jun 20207:00 amRNSInvestor presentation
9th Jun 20204:41 pmRNSSecond Price Monitoring Extn
9th Jun 20204:36 pmRNSPrice Monitoring Extension
9th Jun 20202:06 pmRNSSecond Price Monitoring Extn
9th Jun 20202:00 pmRNSPrice Monitoring Extension
9th Jun 202011:05 amRNSSecond Price Monitoring Extn
9th Jun 202011:00 amRNSPrice Monitoring Extension
29th May 20203:02 pmRNSHolding(s) in Company
29th May 202012:19 pmRNSHolding(s) in Company
29th May 202011:49 amRNSHolding(s) in Company
29th May 20208:30 amRNSHolding(s) in Company
28th May 20202:06 pmRNSSecond Price Monitoring Extn
28th May 20202:01 pmRNSPrice Monitoring Extension
28th May 20201:18 pmRNSApplication for Block Listing
28th May 202012:50 pmRNSHolding(s) in Company
28th May 202011:05 amRNSSecond Price Monitoring Extn
28th May 202011:00 amRNSPrice Monitoring Extension
27th May 202011:35 amRNSResult of General Meeting
27th May 20208:15 amRNSHolding(s) in Company
26th May 202011:58 amRNSHolding(s) in Company
26th May 20209:30 amRNSHolding(s) in Company
22nd May 202011:05 amRNSSecond Price Monitoring Extn
22nd May 202011:00 amRNSPrice Monitoring Extension
22nd May 20209:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.